A 48-year-old man from Delhi participates in a workplace health screening program. Fasting blood glucose is 118 mg/dL (normal <100 mg/dL). He is asymptomatic, has no family history of diabetes, and his BMI is 24 kg/m². The occupational health physician plans to repeat the test in 3 months and counsel lifestyle modification. A colleague argues that the man should be started on metformin immediately to prevent progression to diabetes. Which principle of screening does this disagreement best illustrate?

Explanation

## Screening Principles: Benefits vs. Harms **Key Point:** Screening aims to detect disease early in asymptomatic individuals, but overdiagnosis (detecting disease that would never cause harm) and overtreatment are serious harms that must be weighed against benefits. ### The Impaired Fasting Glucose (IFG) Dilemma **High-Yield:** A single fasting glucose of 100–125 mg/dL defines IFG (impaired fasting glucose), not diabetes. This is a risk state, not a disease diagnosis. Many individuals with IFG never progress to type 2 diabetes, especially those with low additional risk factors. ### Screening Harms vs. Benefits | Aspect | Benefit | Harm | |--------|---------|------| | **Early Detection** | Identifies at-risk individuals before symptoms | Overdiagnosis: labeling healthy people as "prediabetic" | | **Intervention** | Lifestyle modification can prevent/delay diabetes | Overtreatment: pharmacotherapy in low-risk IFG (anxiety, cost, side effects) | | **Progression Rate** | ~11% of IFG progress to diabetes annually | ~89% remain stable or revert to normal; unnecessary medication burden | | **Psychological Impact** | Motivation for lifestyle change | Disease labeling, medicalization of normal variation, reduced quality of life | ### Why Repeat Testing + Lifestyle Counseling Is Appropriate 1. **Confirmation:** A single elevated glucose is insufficient for diagnosis; repeat testing reduces false positives. 2. **Risk Stratification:** Low BMI (24) and no family history suggest low progression risk; intensive pharmacotherapy is premature. 3. **Lifestyle First:** Structured diet and exercise can normalize glucose in ~50% of IFG cases without drugs. 4. **Avoid Overtreatment:** Starting metformin in a low-risk asymptomatic individual exposes him to adverse effects (GI upset, B~12~ deficiency, cost) without proven benefit in this subgroup. **Clinical Pearl:** The Diabetes Prevention Program (DPP) trial showed that lifestyle intervention reduced diabetes incidence by 58% in IFG; metformin reduced it by only 31%. Lifestyle should be first-line. **Mnemonic:** **SCREEN = Seek early, but Confirm, Refine risk, Evaluate harms, Engage shared decision-making, Negotiate treatment** — not all screening findings warrant immediate pharmacotherapy. ### The Four Pillars of Screening Principles ```mermaid flowchart TD A[Screening Program]:::outcome --> B[Principle 1: Disease burden significant?]:::decision A --> C[Principle 2: Test valid & reliable?]:::decision A --> D[Principle 3: Benefits > Harms?]:::decision A --> E[Principle 4: Equitable access & resources?]:::decision D -->|Yes| F[Implement screening]:::action D -->|No| G[Avoid or refine]:::urgent B -->|No| G C -->|No| G E -->|No| G ``` **High-Yield:** The disagreement reflects tension between **sensitivity** (detecting all at-risk individuals) and **specificity/positive predictive value** (avoiding false positives and overtreatment). Screening must optimize both, not maximize sensitivity alone. [cite:Park 26e Ch 9; Harrison 21e Ch 407]